Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 16, Issue 8, Pages 1197-1207Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.16.8.1197
Keywords
amyotrophic lateral sclerosis; clinical trials; excitotoxicity; minocycline; motor neuron degeneration; neuroprotective agents; neurotrophic factors; riluzole
Categories
Ask authors/readers for more resources
Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the treatment of amyotrophic lateral sclerosis, but advances in drug development and screening are substantially increasing the number of potential therapeutic agents. This review provides an overview of clinical trial methodology in annyotrophic lateral sclerosis followed by a systematic evaluation of drugs that are presently in Phase I, II and III clinical trials. There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available